Cyclacel Pharmaceuticals Inc, based in Berkeley Heights, New Jersey, is a clinical-stage biopharmaceutical company focused on developing cancer treatments through programs in cell cycle, transcriptional regulation, and mitosis control. Key projects include fadraciclib, a CDK9 inhibitor for various cancers, and plogosertib, a potent PLK1 inhibitor targeting solid tumors and hematological malignancies.
Cyclacel Pharmaceuticals (CYCC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cyclacel Pharmaceuticals's actual EPS was -$0.72, beating the estimate of -$1.46 per share, resulting in a 50.81% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
